Report to the Congress: Medicare and the Health Care Delivery System, Chapter 3 – Part B drug payment policy issues (2015)

Government Record · Medicare Payment Advisory Commission (MedPAC) · June 2015

Medicare Payment Advisory Commission (MedPAC), 2015-06: MedPAC's June 2015 chapter explains that Medicare pays ASP plus 6% regardless of acquisition cost and that the percentage add-on can reward selection of higher-priced drugs; it models converting the add-on to a flat fee. Medicare and beneficiaries paid over $19 billion for ASP+6% drugs in 2013.

concern has been expressed that the 6 percent add-on to the ASP may create incentives for use of higher priced drugs when lower priced alternatives are available.

p. 61

Medicare Payment Advisory Commission (MedPAC), 2015-06: MedPAC's June 2015 chapter explains that Medicare pays ASP plus 6% regardless of acquisition cost and that the percentage add-on can reward selection of higher-priced drugs; it models converting the add-on to a flat fee. Medicare and beneficiaries paid over $19 billion for ASP+6% drugs in 2013. Congressional advisory body, no funder or conflicts. No product or maker. Comparator: policy options (flat add-on) modelled against current ASP+6%. The same chapter covers 340B hospitals' larger spread (cross-reference CHE-10).